AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27103215 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilemma-focused therapy (DFT)
Number of subjects: 128
Study 27103215 — intervention group
Group type: COMPARATOR
Intervention: Individual manualized CBT
Number of subjects: 128
Study 24662855 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-guided dosing (50 mg twice a day)
Number of subjects: 87
Study 24662855 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (30 mg twice a day)
Number of subjects: 87
Study 23860520 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus Tamoxifen (TAM)
Number of subjects: 110
Study 23860520 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) alone
Number of subjects: 110
Study 20962021 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 704
Study 20962021 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 704
Study 20962021 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle program of weight management
Number of subjects: 704
Study 19564296 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record-based clinical alerts for influenza vaccine at intervention sites
Number of subjects: 11919
Study 19564296 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no alerts)
Number of subjects: 11919
Study 17309130 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM-1 levels in SLE patients
Number of subjects: 68
Study 17309130 — intervention group
Group type: EXPERIMENTAL
Intervention: sVCAM-1 levels in SLE patients
Number of subjects: 68
Study 17309130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin levels in SLE patients
Number of subjects: 68
Study 17309130 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR in SLE patients
Number of subjects: 68
Study 17309130 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA beta-cell in SLE patients
Number of subjects: 68
Study 17309130 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM-1 variability in SLE patients
Number of subjects: 68
Study 17309130 — intervention group
Group type: COMPARATOR
Intervention: sICAM-1 levels in controls
Number of subjects: 68
Study 17309130 — intervention group
Group type: COMPARATOR
Intervention: sVCAM-1 levels in controls
Number of subjects: 68
Study 15459165 — intervention group
Group type: EXPERIMENTAL
Intervention: Private practitioners
Number of subjects: 1101
Study 15459165 — intervention group
Group type: COMPARATOR
Intervention: Public practitioners
Number of subjects: 1101
Study 11438321 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg of recombinant hCG SC
Number of subjects: 297
Study 11438321 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg of recombinant hCG SC
Number of subjects: 297
Study 11438321 — intervention group
Group type: COMPARATOR
Intervention: 10,000 U USP urinary hCG IM
Number of subjects: 297
Study 9849035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 40
Study 9849035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 7727578 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 0
Study 7727578 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine (ddC)
Number of subjects: 0
Study 7727578 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 0
Study 7727578 — intervention group
Group type: COMPARATOR
Intervention: No antiretroviral treatment (No Rx)
Number of subjects: 0
Study 2035339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medicamentous therapy and percutaneous drainage
Number of subjects: 33
Study 2035339 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole and chlorochin
Number of subjects: 33
Study 6948504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (smoking cessation and dietary changes)
Number of subjects: 1232
Study 6948504 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1232
Study 30797542 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanteric Support Plate (TSP)
Number of subjects: 100
Study 30797542 — intervention group
Group type: COMPARATOR
Intervention: No Trochanteric Support Plate (NoTSP)
Number of subjects: 100
Study 28704587 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 50, 125, 300 or 600 mg weekly
Number of subjects: 100
Study 28704587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 2.5 mg daily
Number of subjects: 100
Study 28704587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25957330 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (CRT) followed by surgery and four cycles of postoperative adjuvant capecitabine and oxaliplatin (CAPOX)
Number of subjects: 108
Study 25957330 — intervention group
Group type: COMPARATOR
Intervention: Four cycles of CAPOX followed by CRT and surgery
Number of subjects: 108
Study 23621902 — intervention group
Group type: EXPERIMENTAL
Intervention: BOC/RGT
Number of subjects: 0
Study 23621902 — intervention group
Group type: EXPERIMENTAL
Intervention: BOC/PR48
Number of subjects: 0
Study 23621902 — intervention group
Group type: COMPARATOR
Intervention: PR48
Number of subjects: 0
Study 23621902 — intervention group
Group type: EXPERIMENTAL
Intervention: BOC/PR48 vs BOC/RGT
Number of subjects: 0
Study 21823273 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz electroacupuncture (EA)
Number of subjects: 50
Study 21823273 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz electroacupuncture (EA)
Number of subjects: 50
Study 21823273 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz electroacupuncture (EA)
Number of subjects: 50
Study 19478637 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (100 kV(p) and 140 eff mA s)
Number of subjects: 210
Study 19478637 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (80 kV(p) and 180 eff mA s)
Number of subjects: 210
Study 19478637 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (standard protocol, 120 kV(p) and 100 eff mA s)
Number of subjects: 210
Study 17968938 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 80 mg/day
Number of subjects: 210
Study 17968938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 14988901 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs)
Number of subjects: 0
Study 14988901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary brachytherapy (IBT)
Number of subjects: 0
Study 11802510 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g t.d.s. for 4 weeks (SAC group; n = 60)
Number of subjects: 120
Study 11802510 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg b.d. for the first 7 days and 40 mg o.d. for the next 3 weeks (PAC group; n = 60)
Number of subjects: 120
Study 9919095 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission telephone intervention
Number of subjects: 0
Study 9919095 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8116719 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle
Number of subjects: 248
Study 8116719 — intervention group
Group type: EXPERIMENTAL
Intervention: Explora
Number of subjects: 248
Study 8116719 — intervention group
Group type: COMPARATOR
Intervention: Accurette
Number of subjects: 248
Study 1685675 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 9
Study 1685675 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 9
Study 1685675 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg
Number of subjects: 9
Study 7449642 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment with prednisolone and azathioprine
Number of subjects: 9
Study 7449642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunosuppressive treatment)
Number of subjects: 9
Study 31355249 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction nomogram based on serum long noncoding RNA (lncRNA)
Number of subjects: 242
Study 31355249 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of lnc-EPS15L1-2:1 in HCC cell lines
Number of subjects: 242
Study 27588568 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal iron 28 mg (LI28)
Number of subjects: 80
Study 27588568 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal iron 14 mg (LI14)
Number of subjects: 80
Study 27588568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous iron 30 mg (FI)
Number of subjects: 80
Study 27588568 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 80
Study 26497059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (Group S)
Number of subjects: 90
Study 26497059 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative methylprednisolone before sevoflurane anesthesia (Group S + MP)
Number of subjects: 90
Study 26497059 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol (Group C)
Number of subjects: 90
Study 24106757 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% S. flavescens extract cream
Number of subjects: 0
Study 22030046 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexpensive-modified transobturator vaginal tape procedure
Number of subjects: 156
Study 22030046 — intervention group
Group type: COMPARATOR
Intervention: GYNECARE TVT-O procedure
Number of subjects: 156
Study 22030046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 156
Study 18761603 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN alpha‐2a monotherapy (n = 59)
Number of subjects: 144
Study 18761603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (n = 61)
Number of subjects: 144
Study 18761603 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN alpha‐2a monotherapy with low viraemia (≤300,000 IU/mL)
Number of subjects: 144
Study 18761603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with low viraemia (≤300,000 IU/mL)
Number of subjects: 144
Study 18761603 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN alpha‐2a monotherapy with intermediate viraemia (>300,000 IU/mL and ≤700,000 IU/mL)
Number of subjects: 144
Study 18761603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with intermediate viraemia (>300,000 IU/mL and ≤700,000 IU/mL)
Number of subjects: 144
Study 18761603 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN alpha‐2a monotherapy with high viraemia (>700,000 IU/mL)
Number of subjects: 144
Study 18761603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with high viraemia (>700,000 IU/mL)
Number of subjects: 144
Study 17845650 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.125% with sufentanil (1 microg/xml)
Number of subjects: 72
Study 17845650 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine 0.0625% with sufentanil (1 microg/xml)
Number of subjects: 72
Study 15576515 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 195
Study 15576515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 11468498 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care program supervised by a psychiatrist and a primary care expert, providing intervention services for 12 months using antidepressant medications and Problem Solving Treatment in Primary Care.
Number of subjects: 1750
Study 11468498 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 1750
Study 9503770 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetics (various types including vapocoolants, needleless injection systems, iontophoresis, EMLA Cream)
Number of subjects: 0
Study 8061739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (enteral administration of a balanced glucose-electrolyte solution)
Number of subjects: 0
Study 8061739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solutions with additional benefits
Number of subjects: 0
Study 8061739 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 3361903 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (dose not specified)
Number of subjects: 0
Study 3361903 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy (not specified)
Number of subjects: 0
Study 3361903 — intervention group
Group type: EXPERIMENTAL
Intervention: Public self-awareness (normal vs high)
Number of subjects: 0
Study 29504427 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06438179/GP1111
Number of subjects: 151
Study 29504427 — intervention group
Group type: COMPARATOR
Intervention: infliximab‐EU
Number of subjects: 151
Study 29504427 — intervention group
Group type: COMPARATOR
Intervention: infliximab‐US
Number of subjects: 151
Study 29504427 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 151
Study 28186711 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose statin exposure (EM 1)
Number of subjects: 404129
Study 28186711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative standardized statin dose at index date (EM 2)
Number of subjects: 404129
Study 28186711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative standardized statin dose in the 180 days prior to index date (EM 3)
Number of subjects: 404129
Study 26320283 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 58
Study 26320283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23248351 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention delivered by lay health educators (LHEs)
Number of subjects: 228
Study 23248351 — intervention group
Group type: COMPARATOR
Intervention: Control, weight-loss intervention
Number of subjects: 228
Study 21239518 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg once daily for 13 days)
Number of subjects: 21
Study 21239518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18495031 — intervention group
Group type: EXPERIMENTAL
Intervention: Real moxibustion
Number of subjects: 0
Study 18495031 — intervention group
Group type: COMPARATOR
Intervention: Sham moxibustion
Number of subjects: 0
Study 18495031 — intervention group
Group type: COMPARATOR
Intervention: Natural course of events
Number of subjects: 0
Study 17181082 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled nursing intervention focused on education and counseling
Number of subjects: 45
Study 17181082 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 45
Study 14531591 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilled resin‐based composite (Durafill VS) with no enamel bevel
Number of subjects: 105
Study 14531591 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilled resin‐based composite (Durafill VS) with beveled enamel margin
Number of subjects: 105
Study 14531591 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin‐based composite (Natural Flow) with beveled enamel margin
Number of subjects: 105
Study 14531591 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin‐based composite (Natural Flow) with no enamel bevel
Number of subjects: 105
Study 11100397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse contour (PC) technique
Number of subjects: 40
Study 11100397 — intervention group
Group type: COMPARATOR
Intervention: Whole-body impedance cardiography (ICG)
Number of subjects: 40
Study 11100397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (PC and ICG)
Number of subjects: 40
Study 8741955 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg/day nicotine skin patch for smokers
Number of subjects: 17
Study 8741955 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg/day nicotine skin patch for nonsmokers
Number of subjects: 17
Study 8741955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine skin patch (both dosages)
Number of subjects: 17
Study 8741955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine skin patch (smokers only)
Number of subjects: 17
Study 1422929 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed circuit ventilation (ELSA de Gambro ventilator)
Number of subjects: 110
Study 1422929 — intervention group
Group type: COMPARATOR
Intervention: Open circuit ventilation (Siemens 900 B ventilator)
Number of subjects: 110
Study 1422929 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed circuit ventilation
Number of subjects: 110
Study 1422929 — intervention group
Group type: COMPARATOR
Intervention: Open circuit ventilation
Number of subjects: 110
Study 3917352 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, Adriamycin, and 5-fluorouracil)
Number of subjects: 0
Study 3917352 — intervention group
Group type: COMPARATOR
Intervention: L-PAM (L-phenylalanine mustard)
Number of subjects: 0
Study 3917352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed rotation of TM (triethylenethiophosphoramide) and CAF
Number of subjects: 0
Study 3917352 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment with TM followed by CAF upon failure
Number of subjects: 0
Study 3917352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed rotation of TM and CAF
Number of subjects: 0
Study 3917352 — intervention group
Group type: COMPARATOR
Intervention: Initial treatment with TM
Number of subjects: 0
Study 3917352 — intervention group
Group type: COMPARATOR
Intervention: L-PAM
Number of subjects: 0
Study 30980223 — intervention group
Group type: EXPERIMENTAL
Intervention: pedometer plus access to an internet‐mediated PA intervention
Number of subjects: 112
Study 30980223 — intervention group
Group type: COMPARATOR
Intervention: pedometer alone
Number of subjects: 112
Study 28661062 — intervention group
Group type: COMPARATOR
Intervention: Haemoglobin trigger for RBCT < 9.7 g dL-1 (arm A)
Number of subjects: 133
Study 28661062 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin trigger for RBCT < lower normal level (female: 11.5 g dL-1, male: 13.1 g dL-1) (arm B)
Number of subjects: 133
Study 27484823 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention combining workshops, posters, testing performance feedback, and continuous support.
Number of subjects: 460
Study 27484823 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in practices with payments for chlamydia screening prior to the intervention.
Number of subjects: 460
Study 27484823 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in practices with 6-15 staff.
Number of subjects: 460
Study 24553909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 927
Study 24553909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 927
Study 24553909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study 24553909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (initial placebo patients starting at wk 16 or wk 24)
Number of subjects: 927
Study 22093158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase as an adjuvant to lidocaine
Number of subjects: 20
Study 22093158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study 21048970 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine (AS+AQ) monthly
Number of subjects: 2227
Study 21048970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2227
Study 21048970 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly sulphadoxine‐pyrimethamine (SP) or AS+AQ
Number of subjects: 2227
Study 16954409 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin alpha
Number of subjects: 241
Study 16954409 — intervention group
Group type: COMPARATOR
Intervention: uFSH
Number of subjects: 241
Study 16954409 — intervention group
Group type: COMPARATOR
Intervention: hMG
Number of subjects: 241
Study 16258091 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening using serum CA125 interpreted with the ROC algorithm; participants with normal results returned to annual screening, intermediate results had repeat CA125 testing, elevated values underwent transvaginal ultrasound (TVS).
Number of subjects: 6682
Study 16258091 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC algorithm screening strategy
Number of subjects: 6682
Study 12383808 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5‐fluorouracil (50 mg/ml for 5 minutes)
Number of subjects: 115
Study 12383808 — intervention group
Group type: COMPARATOR
Intervention: Topical mitomycin C (0.2 mg/ml for 2 minutes)
Number of subjects: 115
Study 10440143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (1 g/day for 2 days)
Number of subjects: 300
Study 10440143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 7580056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Jiangu (BSJG) capsule
Number of subjects: 34
Study 7580056 — intervention group
Group type: COMPARATOR
Intervention: Calcium treatment
Number of subjects: 34
Study 2181310 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan (0.2 mg per kilogram of body weight per day for five days, repeated every four to six weeks for up to 12 cycles)
Number of subjects: 222
Study 2181310 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan (same regimen as above)
Number of subjects: 222
Study 2181310 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal 32P (15 mCi) at the time of surgery
Number of subjects: 222
Study 94381 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 165
Study 94381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 31903682 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-20-30 training
Number of subjects: 51
Study 31903682 — intervention group
Group type: COMPARATOR
Intervention: MICT
Number of subjects: 51
Study 30483722 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive early rehabilitation for 4 weeks
Number of subjects: 326
Study 30483722 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 326
Study 28946522 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Stabilization Exercises (SSE)
Number of subjects: 113